



Novartis India Limited  
Registered Office:  
Inspire BKC  
Part of 601 & 701  
Bandra Kurla Complex  
Bandra (East)  
Mumbai – 400 051  
Maharashtra, India  
Tel +91 22 50243000  
Fax +91 22 50243010  
Email: india.investors@novartis.com  
CIN No. L24200MH1947PLC006104  
Website: www.novartis.in

December 31, 2021

To,  
The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001  
**Scrip code:** 500672

- Sub.: 1. Intimation of meeting of the Board of Directors of Novartis India Limited (“the Company”)**  
**2. Closure of Trading Window**
- Ref.: 1. Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**  
**2. Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015**

Dear Sir/ Madam,

Please be informed that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 10, 2022, to *inter alia* consider the Unaudited financial results of the Company for the third quarter ending on December 31, 2021 ("said results").

In this connection, further note that pursuant to the Company's Code of Conduct to regulate, monitor and report share trading by Insiders ["the Code"], the trading window for dealing in securities of the Company shall remain closed from Saturday, January 1, 2022 to Saturday, February 12, 2022 (both days inclusive).

The same is being duly communicated to all the Designated Persons under the Code which is available on the Company's website i.e. [www.novartis.in](http://www.novartis.in)

This is for your information.

Thanking You.

Yours sincerely,

**For Novartis India Limited**

**Monaz Noble**  
**Non-Executive Director**